Indian drugmaker Theon Pharma gets warning letter for falsifying records, other issues

Maltese National Agency inspectors found one “critical” deficiency during an inspection conducted in early March. (EMA)

Indian drugmaker Theon Pharmaceuticals was issued a warning letter, citing the company for falsifying records and inadequate quality control systems.

The letter, posted on the EudraGMP website, said inspectors found one “critical” deficiency during an inspection conducted by the Maltese National Agency in early March.

The critical issue concerned “evidence of falsification of documents.” Six “major” deficiencies were documented, which included “inadequate pharmaceutical quality system and documentation management, and deficient control of cross-contamination, manufacturing activities, qualification and validation activities and approval of suppliers.”


Innovative and Flexible Solutions for an End-to-End Patient-Centric, Lean Supply Chain

The trend toward crafting patient-centric clinical trials hold great promise in supporting patients’ willingness and ability to participate in important clinical research. This webinar will explore how recent innovations in forecasting, supply pooling, decentralized processing, labeling, demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric.

The facility, which is located in Village Saini Majra, Tehsil Nalagarh, District Solan, Himachal Pradesh, was also cited for 11 other issues. Currently, the plant isn’t producing drugs for the European market, and the agency recommended Theon Pharma not be granted either marketing authorizations or variation applications to current marketing authorizations for the site.

Theon produces both coated and uncoated tablets at the facility, which has a capacity of making about 700 million units a year, according to the company’s website.

Suggested Articles

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Catalent is buying a site in Italy from Bristol-Myers Squibb that handles biologics along with old-school solid dose production.

Here is some more manufacturing news from the week.